740 related articles for article (PubMed ID: 23485394)
1. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
2. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
3. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
4. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition aggravates adriamycin-induced podocyte injury through intrinsic apoptosis pathway.
Dong J; Jiang Z; Ma G
Exp Cell Res; 2020 May; 390(2):111928. PubMed ID: 32156599
[TBL] [Abstract][Full Text] [Related]
6. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
7. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.
Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; deBock CE; Thorne RF; Allen J; Hersey P; Zhang XD
Cancer Res; 2008 Aug; 68(16):6708-17. PubMed ID: 18701495
[TBL] [Abstract][Full Text] [Related]
12. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
Alas S; Ng CP; Bonavida B
Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
Barbagallo I; Parenti R; Zappalà A; Vanella L; Tibullo D; Pepe F; Onni T; Li Volti G
Acta Histochem; 2015 Oct; 117(8):705-11. PubMed ID: 26493719
[TBL] [Abstract][Full Text] [Related]
14. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells.
Choi AY; Choi JH; Yoon H; Hwang KY; Noh MH; Choe W; Yoon KS; Ha J; Yeo EJ; Kang I
Eur J Pharmacol; 2011 Oct; 668(1-2):115-26. PubMed ID: 21762691
[TBL] [Abstract][Full Text] [Related]
15. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
16. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
Soudan H; Saeed H; Eldemellawy M; Shalaby M; Hassan M; Elkewedi M; El-Nikhely N
Acta Biochim Pol; 2020 Dec; 67(4):561-570. PubMed ID: 33319549
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
